| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MERIT MEDICAL REPORTS THIRD QUARTER 2026 RESULTS: DELIVERS 9% ORGANIC CONSTANT CURRENCY REVENUE GROWTH AND RAISES FULL-YEAR 2026 GUIDANCE |
| 20 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Employment Agreement Page 1 of 15 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Merit Medical Systems, Inc., a Utah corporation (the “Company”), and Sheri Lewis (the “Executive”)... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively |
| 19 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
The Corporation may have such offices, either within or without the State of Utah, as the Board of Directors may designate or as the business of the Corporation may require from time to time. The registered office and principal office of... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure
The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished by Merit Medical Systems, Inc. (“Merit”) to provide historical revenue information disaggregated by its new foundational and therapeutic product... |
| 01 Apr 2026 |
8-K: Regulation FD Disclosure
SOUTH JORDAN, Utah, April 1, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has acquired View Point Medical, Inc. (View Point). Through a merger transacti... |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectively |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 |
| 13 Nov 2025 |
8-K: Regulation FD Disclosure
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis. |
| 03 Nov 2025 |
8-K: Regulation FD Disclosure
On October 17, 2025, Merit Medical Systems, Inc. (“Merit”) filed a Current Report on Form 8-K and related press release announcing it signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX® Medi... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectively |
| 17 Oct 2025 |
8-K: Regulation FD Disclosure
Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. |
| 10 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 3, 2025, the Board of Directors (the “Board”) of Merit Medical Systems, Inc. (“Merit”), in connection with the previously announced resignation of Fred P. Lampropoulos as Merit’s President and Chief Executive Officer (“CEO”) a... |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectively |
| 11 Jul 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors |
| 20 May 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. |
| 19 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2025, Merit Medical Systems, Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). A total of 59,067,132 shares of the Company’s common stock were entitled to vote at the Annual Meeting as o... |
| 24 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively |
Loading...